Cargando…

Reply to ‘Comment on “Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome”’

Detalles Bibliográficos
Autor principal:	Berney, Daniel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294471/ https://www.ncbi.nlm.nih.gov/pubmed/27780194 http://dx.doi.org/10.1038/bjc.2016.347

Ejemplares similares

Comment on ‘Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome’
por: Dell'Oglio, Paolo, et al.
Publicado: (2017)

Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome
por: Berney, Daniel M, et al.
Publicado: (2016)

Reply: Calcium, dairy, and prostate cancer
por: Lee, I-M, et al.
Publicado: (2007)

Reply: Prostate Cancer and Cardiovascular Risk Factors
por: Klimis, Harry, et al.
Publicado: (2023)

The percentage of high‐grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death
por: Berney, Daniel M, et al.
Publicado: (2019)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Reply: ‘Hand pattern indicates risk of prostate cancer’
por: Rahman, A A, et al.
Publicado: (2011)

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
por: Omlin, A, et al.
Publicado: (2014)

Comment on ‘Hand pattern indicates risk of prostate cancer’
por: Cheema, M, et al.
Publicado: (2011)

Comments on the article “Biomarkers for prostate cancer” by Eric Schiffer
por: Marshall, Sumner
Publicado: (2009)

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Local failure in high grade prostate cancer: the importance of local and systemic therapy
por: Kishan, Amar U., et al.
Publicado: (2020)

Author reply to comments
por: Bhalla, Ashu Seith, et al.
Publicado: (2015)

REPLY BY THE AUTHORS: Comment on Polygamy, Sexual Behavior in a Population Under Risk for Prostate Cancer Diagnostic: An Observational Study From the Black Sea Region in Turkey
por: Cirakoglu, Abdullah, et al.
Publicado: (2020)

Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
por: Rosario, D J, et al.
Publicado: (2013)

Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer
por: Cook, Kiri, et al.
Publicado: (2020)

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia - reply to the letter from Cohen, Peehl and Rosenfeld
por: Mantzoros, CS, et al.
Publicado: (1998)

Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer
por: Wong, C K E, et al.
Publicado: (2013)

Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians
por: Gasparrini, Silvia, et al.
Publicado: (2019)

Reply to ‘Comment on Cancer incidence in the United Kingdom: projections to the year 2030'
por: Ahmad, A S, et al.
Publicado: (2013)

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
por: Alvarez, R, et al.
Publicado: (2014)

Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'
por: Shah, S I A, et al.
Publicado: (2013)

Reply: Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort
por: Newton, R, et al.
Publicado: (2006)

Reply to ‘Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system”
por: Bae, Jeong Mo, et al.
Publicado: (2018)

Reply to comment of Prof. Artur Czekierdowski
por: Jakiel, Grzegorz
Publicado: (2017)

Reply to the comment by Osuka et al.
por: Endo, Akira, et al.
Publicado: (2020)

Reply to: Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Johnson, Philip, et al.
Publicado: (2016)

Reply to ‘Comment on ‘A meta-analysis of CXCL12 expression for cancer prognosis”
por: Gordon-Weeks, Alex
Publicado: (2018)

Reply to: Contemporary treatment of children with critical and near-fatal asthma
por: Shein, Steven L, et al.
Publicado: (2016)

Contemporary Grading of Prostate Cancer: The Impact of Grading Criteria and the Significance of the Amount of Intraductal Carcinoma
por: Tzelepi, Vasiliki, et al.
Publicado: (2021)

Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer
por: Sopyllo, Konrad, et al.
Publicado: (2021)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Reply: Height, body mass index, and prostate cancer – a follow-up of 950 000 Norwegian men
por: Engeland, A, et al.
Publicado: (2004)

Reply to TS Clark: ‘High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series’
por: Ahmed, H U, et al.
Publicado: (2009)

The Diagnosis of Prostate Cancer
por: Schulz, Robert J.
Publicado: (2016)

Reply to ‘Comment on ‘Anthropometric measurements and survival after prostate cancer diagnosis”
por: Farris, Megan S., et al.
Publicado: (2018)

Reply: Comment on ‘Estimating the asbestos-related lung cancer burden from mesothelioma mortality'
por: McCormack, V, et al.
Publicado: (2013)

In Reply to the Comment on “The Relationship Between Frailty and Emotional Health in Older Patients With Advanced Cancer”
por: Gilmore, Nikesha, et al.
Publicado: (2022)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Authors' Reply to Comments from Dr. Guan
por: Inoue, Ken-ichiro, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_163mm2pn81e4n9nqc7l7b0j9c8